Gerresheimer (GXI) Aandelenoverzicht
Gerresheimer AG produceert en verkoopt samen met haar dochterondernemingen medicijnverpakkingen, toedieningshulpmiddelen en oplossingen in Duitsland en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 0/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
GXI Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Gerresheimer AG Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €24.66 |
| 52 Week Hoogtepunt | €52.00 |
| 52 Week Laag | €14.83 |
| Bèta | 0.47 |
| 1 maand verandering | -12.12% |
| 3 maanden verandering | 33.51% |
| 1 Jaar Verandering | -48.50% |
| 3 jaar verandering | -77.40% |
| 5 jaar verandering | -73.72% |
| Verandering sinds IPO | -35.70% |
Recent nieuws en updates
Narratiefupdate • Jun 01
GXI: Reporting Delays And Accounting Concerns Will Pressure Long Term Confidence
Analysts have trimmed their price targets on Gerresheimer, with one cut from €34.10 to €26.80 contributing to a modest reduction in the modelled fair value from €24.40 to about €23.37, as concerns around delayed results, accounting issues, and the Bormioli overhang weigh on sentiment. Analyst Commentary Recent research has shifted toward a more cautious stance on Gerresheimer, with several firms moving to neutral ratings and cutting price targets to around €26.80 from about €34.10.
Narratiefupdate • May 03
GXI: FY25 Warning And Deferred Results Will Drive Further Share Weakness
Analysts have trimmed their average price target for Gerresheimer to about €12.90 from €29, citing reduced short- and mid-term estimates following the recent FY25 warning and slightly softer expectations compared with the low end of the company's FY26 guidance. Analyst Commentary Bearish analysts are flagging a more cautious stance on Gerresheimer, pointing to reduced confidence in near term execution and visibility.
Narratiefupdate • Apr 19
GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.Narratiefupdate • Apr 05
GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.Recent updates
Narratiefupdate • Jun 01
GXI: Reporting Delays And Accounting Concerns Will Pressure Long Term Confidence
Analysts have trimmed their price targets on Gerresheimer, with one cut from €34.10 to €26.80 contributing to a modest reduction in the modelled fair value from €24.40 to about €23.37, as concerns around delayed results, accounting issues, and the Bormioli overhang weigh on sentiment. Analyst Commentary Recent research has shifted toward a more cautious stance on Gerresheimer, with several firms moving to neutral ratings and cutting price targets to around €26.80 from about €34.10.Narratiefupdate • May 03
GXI: FY25 Warning And Deferred Results Will Drive Further Share Weakness
Analysts have trimmed their average price target for Gerresheimer to about €12.90 from €29, citing reduced short- and mid-term estimates following the recent FY25 warning and slightly softer expectations compared with the low end of the company's FY26 guidance. Analyst Commentary Bearish analysts are flagging a more cautious stance on Gerresheimer, pointing to reduced confidence in near term execution and visibility.Narratiefupdate • Apr 19
GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.Narratiefupdate • Apr 05
GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.Narratiefupdate • Mar 22
GXI: FY25 Warning And Deferred Results Will Pressure Shares Further
Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.Narratiefupdate • Mar 07
GXI: Reset After FY25 Warning Will Set Up Future Earnings Reappraisal
Analysts have reduced their price target for Gerresheimer to about €46 from about €52, citing a higher discount rate and lower assumed future P/E, along with updated revenue growth and profit margin assumptions, as well as recent cautious Street research following the FY25 warning. Analyst Commentary The latest Street research has turned more cautious after the FY25 warning, with at least one major broker shifting to a Sell stance and cutting its price target to €12.90 from €29.Narratiefupdate • Feb 21
GXI: Deferred Results And Softer Outlook Will Keep Shares Fairly Priced
Analysts have adjusted their price target on Gerresheimer to €18.90 from €22.00 as they now apply a slightly higher discount rate, a lower assumed revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Gerresheimer issued earnings guidance for 2026, targeting revenues of around €2.3b to €2.4b (company guidance).Analyseartikel • Feb 10
Investors Don't See Light At End Of Gerresheimer AG's (ETR:GXI) Tunnel
Gerresheimer AG's ( ETR:GXI ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a buy right now compared...Narratiefupdate • Feb 06
GXI: Index Inclusion And Higher P/E Assumptions Will Support Long-Term Confidence
Analysts have modestly lifted their price target for Gerresheimer, citing small adjustments to fair value and discount rate assumptions, as well as revised expectations for revenue growth, profit margins and future P/E. What's in the News Gerresheimer AG has been added to the Germany SDAX (Total Return) Index, highlighting its inclusion in this segment of the German equity market (Key Developments).Narratiefupdate • Jan 23
GXI: Reset Expectations Will Set Up Future Reappraisal Of Earnings Quality
Analysts have trimmed their average price target on Gerresheimer to €30 from €55. The change reflects updated expectations for revenue growth, profit margins and future P/E multiples following recent research reviews.Narratiefupdate • Jan 09
GXI: Profit Warnings Reset Expectations While Drug Delivery Platform Will Drive Reassessment
Gerresheimer's updated fair value estimate has been cut from about €97.07 to around €51.97 as analysts reset price targets sharply lower, citing reduced earnings visibility, a higher discount rate and increased uncertainty following recent profit warnings and rating downgrades. Analyst Commentary Recent Street research has turned more cautious on Gerresheimer, with several firms lowering price targets and adjusting ratings following profit warnings and reduced visibility on the investment case.Narratiefupdate • Dec 25
GXI: Profit Warnings And Weak Outlook Will Pressure Shares Further
Gerresheimer's analyst price target has been cut sharply from about EUR 47.50 to EUR 22.00, as analysts factor in lower growth, thinner margins, a higher discount rate, and reduced valuation multiples following multiple target downgrades and rising uncertainty around the investment case. Analyst Commentary Bearish analysts have made a series of aggressive downward revisions to Gerresheimer's valuation, cutting price targets from prior levels as high as EUR 99.30 to a range between EUR 23 and EUR 46.Narratiefupdate • Dec 11
GXI: Long-Term Sector Demand Will Support Confidence Despite Recent Profit Warnings
Analysts have cut their price target on Gerresheimer sharply, from roughly EUR 35 to about EUR 34. This reflects reduced fair value estimates as they factor in lower visibility on the investment case, successive target downgrades across the Street, and ongoing uncertainty following multiple profit warnings.Analyseartikel • Nov 30
These 4 Measures Indicate That Gerresheimer (ETR:GXI) Is Using Debt In A Risky Way
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narratiefupdate • Nov 27
GXI: Long-Term Sector Demand Will Support Confidence After Recent Leadership Change
Gerresheimer's analyst price targets have been significantly reduced recently, with analysts citing ongoing uncertainties and diminished near-term visibility as key factors for the downward revision. Previous targets exceeded €50, but new values are now in the €23 to €46 range.Narratiefupdate • Nov 10
GXI: Confidence Will Remain Despite Current Uncertainties And Leadership Transition
Gerresheimer's analyst fair value target has been revised downward from €37.84 to €34.62. This change reflects recent broad cuts in price targets by analysts, who cite low visibility and ongoing uncertainties around the company's outlook.Analyseartikel • Nov 02
Lacklustre Performance Is Driving Gerresheimer AG's (ETR:GXI) 27% Price Drop
To the annoyance of some shareholders, Gerresheimer AG ( ETR:GXI ) shares are down a considerable 27% in the last...Narratiefupdate • Oct 27
Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead
Gerresheimer's analyst price target has been significantly reduced from €56.36 to €37.84. Analysts cite heightened uncertainties, reduced growth expectations, and a lack of near-term catalysts as reasons for this more cautious outlook.Narratiefupdate • Oct 13
New Production Lines In Lohr And Skopje Will Improve Efficiency
Analysts have lowered their price target for Gerresheimer from €63.72 to €56.36. They cite more cautious expectations for revenue growth and profitability going forward.Narratiefupdate • Sep 23
New Production Lines In Lohr And Skopje Will Improve Efficiency
The downward revision in Gerresheimer’s price target reflects recent declines in both net profit margin and consensus revenue growth forecasts, resulting in a reduced fair value estimate from €66.84 to €63.72. What's in the News Wolf Lehmann appointed as incoming CFO, succeeding Dr. Bernd Metzner; Lehmann brings nearly 30 years of international finance and management experience.Analyseartikel • Sep 18
Why We're Not Concerned About Gerresheimer AG's (ETR:GXI) Share Price
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Analyseartikel • Jul 31
Here's Why Gerresheimer (ETR:GXI) Is Weighed Down By Its Debt Load
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Jun 18
Positive Sentiment Still Eludes Gerresheimer AG (ETR:GXI) Following 28% Share Price Slump
Unfortunately for some shareholders, the Gerresheimer AG ( ETR:GXI ) share price has dived 28% in the last thirty days...Analyseartikel • May 30
Shareholders May Be Wary Of Increasing Gerresheimer AG's (ETR:GXI) CEO Compensation Package
Key Insights Gerresheimer's Annual General Meeting to take place on 5th of June Salary of €1.15m is part of CEO Dietmar...Analyseartikel • May 29
Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Gerresheimer AG ( ETR:GXI ) will pay a dividend of €1.25 on the 10th of June. Based on this payment, the dividend yield...Analyseartikel • May 14
Is There Now An Opportunity In Gerresheimer AG (ETR:GXI)?
Gerresheimer AG ( ETR:GXI ), is not the largest company out there, but it led the XTRA gainers with a relatively large...Analyseartikel • Apr 24
Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Gerresheimer AG ( ETR:GXI ) has announced that it will pay a dividend of €1.25 per share on the 10th of June. Based on...Analyseartikel • Apr 19
Earnings Troubles May Signal Larger Issues for Gerresheimer (ETR:GXI) Shareholders
Gerresheimer AG's ( ETR:GXI ) recent weak earnings report didn't cause a big stock movement. However, we believe that...Analyseartikel • Apr 11
It's Down 32% But Gerresheimer AG (ETR:GXI) Could Be Riskier Than It Looks
Gerresheimer AG ( ETR:GXI ) shares have had a horrible month, losing 32% after a relatively good period beforehand. The...Analyseartikel • Apr 10
Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
Gerresheimer AG's ( ETR:GXI ) investors are due to receive a payment of €1.25 per share on 10th of June. This means the...Analyseartikel • Mar 05
Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
The board of Gerresheimer AG ( ETR:GXI ) has announced that it will pay a dividend on the 10th of June, with investors...Analyseartikel • Feb 25
Why Investors Shouldn't Be Surprised By Gerresheimer AG's (ETR:GXI) 25% Share Price Surge
Gerresheimer AG ( ETR:GXI ) shareholders would be excited to see that the share price has had a great month, posting a...
Nieuw narratief • Feb 09
Expansion Into High-Margin Biologics And Devices Indicates Strong Future Prospects
Strategic expansion into high-margin segments like drug delivery systems and ready-to-use vials could enhance revenue and EBITDA margins significantly.Analyseartikel • Jan 12
Is Gerresheimer (ETR:GXI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Dec 26
Is It Time To Consider Buying Gerresheimer AG (ETR:GXI)?
While Gerresheimer AG ( ETR:GXI ) might not have the largest market cap around , it saw significant share price...Analyseartikel • Oct 03
Gerresheimer AG Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next
It's been a mediocre week for Gerresheimer AG ( ETR:GXI ) shareholders, with the stock dropping 20% to €77.50 in the...Analyseartikel • Sep 29
Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Aug 31
Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 31x Gerresheimer AG ( ETR:GXI ) may be sending very bearish signals at the...Rendement voor aandeelhouders
| GXI | DE Life Sciences | DE Markt | |
|---|---|---|---|
| 7D | -6.2% | -2.7% | -2.9% |
| 1Y | -48.5% | -6.7% | -0.8% |
Rendement versus industrie: GXI presteerde slechter dan de German Life Sciences -sector, die het afgelopen jaar een rendement van -6.7 % opleverde.
Rendement versus markt: GXI presteerde slechter dan German Market, dat het afgelopen jaar een rendement van -0.8 % opleverde.
Prijsvolatiliteit
| GXI volatility | |
|---|---|
| GXI Average Weekly Movement | 11.7% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 2.7% |
Stabiele aandelenkoers: De aandelenkoers van GXI is de afgelopen 3 maanden volatiel geweest in vergelijking met de German markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van GXI is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1864 | 13,535 | Uwe Röehrhoff | www.gerresheimer.com |
Gerresheimer AG produceert en verkoopt samen met haar dochterondernemingen medicijnverpakkingen, toedieningshulpmiddelen en oplossingen in Duitsland en internationaal. Het bedrijf is actief via drie divisies: Plastics & Devices, Primary Packaging Glass en Advanced Technologies. Het bedrijf biedt voorvulbare spuiten, plastic en glazen verpakkingsoplossingen, flacons, glazen patronen en ampullen, flessen en containers, en glazen flessen en potten, evenals doppen, sluitingen, applicators en accessoires; ontwikkeling, industrialisatie en contractproductie van medicijnafleveringsprogramma's; project- en kwaliteitsmanagement; en medicijnafgiftesystemen, waaronder inhalatoren, injectie/auto-injectoren, pen-injectoren, infusiesystemen en inhalatiebeoordeling, auto-injectoren en andere diensten.
Gerresheimer AG Samenvatting
| GXI fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €851.76m |
| Inkomsten(TTM) | €23.35m |
| Inkomsten(TTM) | €2.25b |
36.5x
Koers/Winstverhouding0.4x
P/S-verhoudingIs GXI overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| GXI resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €2.25b |
| Kosten van inkomsten | €1.65b |
| Brutowinst | €605.15m |
| Overige uitgaven | €581.80m |
| Inkomsten | €23.35m |
Laatst gerapporteerde inkomsten
Aug 31, 2025
Volgende inkomensdatum
Jul 14, 2026
| Winst per aandeel (EPS) | 0.68 |
| Brutomarge | 26.89% |
| Nettowinstmarge | 1.04% |
| Schuld/Eigen Vermogen Verhouding | 155.5% |
Hoe presteerde GXI op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.2%
Huidig dividendrendement6%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/10 22:59 |
| Aandelenkoers aan het einde van de dag | 2026/06/10 00:00 |
| Inkomsten | 2025/08/31 |
| Jaarlijkse inkomsten | 2024/11/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Gerresheimer AG wordt gevolgd door 34 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jonathon Unwin | Barclays |
| Pallav Mittal | Barclays |
| Gaurav Jain | Barclays |